ADMA Biologics slips after short‑seller Culper Research alleges inflated sales

Shares of ADMA Biologics ADMA.O fall 7.7% to $12.55

Culper Research says it is short on ADMA

Culper accuses the company of inflating its sales figures by pushing excess inventory onto distributors

Culper estimates that ADMA's revenues fell 3% in 2025, not the 20% growth the company reported for the year

ADMA did not immediately respond to a Reuters request for comment

Including session's moves, stock down 30.9% YTD